Shanghai Henlius Biotech's quarterly market cap
increased
from Jun. 2023 (HK$6,033 Mil) to Dec. 2023 (HK$7,555 Mil) and
increased
from Dec. 2023 (HK$7,555 Mil) to Jun. 2024 (HK$12,419 Mil).
Shanghai Henlius Biotech's annual market cap
declined
from Dec. 2021 (HK$11,984 Mil) to Dec. 2022 (HK$6,957 Mil) but then
increased
from Dec. 2022 (HK$6,957 Mil) to Dec. 2023 (HK$7,555 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Shanghai Henlius Biotech's Enterprise Value for Today is HK$17,608 Mil.
Shanghai Henlius Biotech Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Shanghai Henlius Biotech's Market Cap
For the Biotechnology subindustry, Shanghai Henlius Biotech's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Henlius Biotech's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Henlius Biotech's Market Cap distribution charts can be found below:
* The bar in red indicates where Shanghai Henlius Biotech's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Shanghai Henlius Biotech's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Henlius Biotech (HKSE:02696) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Shanghai Henlius Biotech Market Cap Related Terms
Thank you for viewing the detailed overview of Shanghai Henlius Biotech's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Shanghai Henlius Biotech Inc is a biopharmaceutical company in China with the vision to offer affordable and innovative biologics for patients with a focus on oncology and autoimmune diseases. The Group is engaged in biopharmaceutical R&D, biopharmaceutical services, and biopharmaceutical production and sales. It operates in Mainland China and Overseas. The company products include HLX01 Rituximab, HLX02(trastuzumab), and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:02696 has been successfully added to your 